Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.
Lancia, Pauline; Adam de Beaumais, Tiphaine; Elie, Valéry; Garaix, Florentine; Fila, Marc; Nobili, François; Ranchin, Bruno; Testevuide, Pascale; Ulinski, Tim; Zhao, Wei; Deschênes, Georges; Jacqz-Aigrain, Evelyne.
; 33(6): 1045-1055, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29399716
Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population.
Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.
Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome.
The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.
Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.